Acumen Pharmaceuticals, Inc. Q3 FY2024 earnings call

• Clinical progress: ALTITUDE-AD Phase II study enrolling >75 sites across North America, U.K., EU, anticipates completion in first half of 2025; Phase I study of subcutaneous sabirnetug to have top line results Q1 2025. • CTAD meeting: Blood-based biomarkers and real-world use of Leqembi discussed; Acumen positioned to capitalize on momentum. • R&D Day: Virtual event with details on sabirnetug's mechanism, Phase I results, and Phase II plans. • Organizational: Appointed Dr. Amy Schacterle as Chief Regulatory Officer and Head of Quality; thanked Janice Hitchcock for regulatory efforts.

No detailed product segment financial performance with revenue contribution % provided. R&D expenses in Q3 2024 were $27.2 million, increase due to ALTITUDE-AD trial spending. G&A expenses were $5 million, roughly flat year-over-year. Net loss was $29.8 million with net cash burn of ~$23 million.

• Cash runway: Approximately $259 million in cash and marketable securities as of September 30, expected to last into first half of 2027. • Resources: Have resources to support Phase II study and advance subcutaneous sabirnetug.

• Risks related to forward-looking statements, including factors from SEC filings that could cause actual results to differ materially from forward-looking statements.

Q: On the subcutaneous study, what data to expect and next steps?

A: Phase I is a PK bioavailability study in healthy volunteers; data needed to inform next steps for subcutaneous sabirnetug.

Q: Thoughts on interim looks for ALTITUDE-AD and ARIA data?

A: No anticipation of interim looks, preserving study integrity; ARIA data will be disclosed at end of the blinded trial.

Q: Confidence in subcu pivotal data?

A: Need Phase I data first, then determine if Phase 2 subcu is needed for pivotal.

Q: Leading indicators for ALTITUDE-AD?

A: Rapid enrollment rate, exceeding initial expectations, with >75 sites enrolling.

Q: Patient population for ALTITUDE-AD?

A: Targets MCI or mild dementia with amyloid PET or CSF-based pathology, considering disease course and biomarker data.

Q: ARIA burden with sabirnetug?

A: Lower ARIA rates anticipated due to mechanism; clinical approach to ARIA is evolving among clinicians